Assembly Biosciences (V7B) Price & Analysis

3 Followers

V7B Stock Chart & Stats

€25.50

-€0.10(-0.62%)

At close: Jan 08 4:00 PM EST

€25.50

-€0.10(-0.62%)

Day’s Range― - ―

52-Week Range€15.05 - €33.50

Previous CloseN/A

Volume700.00

Average Volume (3M)158.00

Market Cap

€459.43M

Enterprise Value€244.87

Total Cash (Recent Filing)€226.60M

Total Debt (Recent Filing)€2.49M

Price to Earnings (P/E)―

Beta0.75

Next Earnings

Aug 12, 2026

EPS Estimate

-0.63

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.58

Shares Outstanding19,817,250

10 Day Avg. Volume188

30 Day Avg. Volume158

Financial Highlights & Ratios

PEG Ratio0.67

Price to Book (P/B)1.84

Price to Sales (P/S)5.27

P/FCF Ratio-9.26

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€40.21

Price Target Upside57.68% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-1.49

Revenue Forecast (FY)€39.93M

Bulls Say, Bears Say

Bulls Say

Strong Balance SheetVery low leverage and substantial equity provide durable financial flexibility for a clinical-stage biotech. This reduces bankruptcy risk, supports multi-year R&D programs, and lets management prioritize development decisions rather than near-term creditor constraints, a lasting structural advantage.

Recent $107.4M FinancingA large institutional-backed equity raise materially extends runway and funds planned Phase 2 activities. Durable impact: it lowers immediate funding pressure, increases strategic optionality for partnerships or additional indications, and gives time to de-risk clinical assets before next financings.

Pipeline Expansion (ABI-6250)Broadening ABI-6250 into cholestatic liver diseases and planning Phase 2 trials diversifies the program beyond HDV. This structural shift increases addressable patient populations, de-risks single-indication dependence, and improves long-term partnering and commercialization prospects if trials succeed.

Bears Say

High Cash BurnSustained negative operating and free cash flow shows the company is consuming capital to fund R&D. Over months this trend necessitates repeated external financing, which can dilute shareholders and constrain the ability to run parallel trials or scale programs without additional capital raises.

Negative Profitability & Volatile RevenueVolatile, collaboration-driven revenue and persistent negative margins mean the business cannot self-fund development. Revenue swings reduce predictability for planning multi-year trials and heighten reliance on partners or financings, a structural limitation for independent long-term sustainability.

Reliance On Equity And Dilution RiskDependence on equity issuances and an expanded stock incentive pool creates recurring dilution risk. Structurally, this can erode per-share economics over time, pressure future returns, and alter investor alignment if frequent raises are needed to support multi-indication clinical programs.

Assembly Biosciences News

Assembly Biosciences price target raised to $45 from $40 at Mizuho

Mizuho raised the firm’s price target on Assembly Biosciences (ASMB) to $45 from $40 and keeps an Outperform...

1M ago

ASMB

Assembly Biosciences Expands Equity Plans, Reelects Board

Assembly Biosciences ( ($ASMB) ) has shared an announcement. At its annual meeting of stockholders on June 4,...

2M ago

ASMB

Assembly Biosciences Completes Significant Equity Offering Financing

Assembly Biosciences ( ($ASMB) ) has issued an update. On May 21, 2026, Assembly Biosciences entered an underwriting...

2M ago

ASMB

Assembly Biosciences Expands ABI-6250 Liver Disease Program

Assembly Biosciences ( ($ASMB) ) has provided an announcement. On May 22, 2026, Assembly Biosciences announced that it...

2M ago

ASMB

Assembly Biosciences announces expansion of ABI-6250 clinical development

Assembly Biosciences (ASMB) announced plans to expand the clinical development of ABI-6250, its oral entry inhibitor candidate for...

2M ago

ASMB

Analyst Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target Amid Pipeline Progress and 2028 Cash Runway

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Assembly Biosciences today and set a price target...

2M ago

ASMB

Assembly Biosciences reports Q1 EPS (54c), consensus (64c)

Reports Q1 revenue $8.21M, consensus $6.95M. “The first quarter reflected steady progress across our portfolio as we continue...

3M ago

ASMB

ASMB Earnings this Week: How Will it Perform?

Assembly Biosciences Inc (ASMB) is scheduled to report 1st quarter earnings on 05/07/2026. Regarding Q1 estimates, Wall Street...

3M ago

ASMB

Assembly Biosciences price target raised to $43 from $39 at Guggenheim

Guggenheim raised the firm’s price target on Assembly Biosciences (ASMB) to $43 from $39 and keeps a Buy...

4M ago

ASMB

GILD

Assembly Biosciences Adopts 2026 Performance-Based Bonus Plan

Assembly Biosciences ( ($ASMB) ) has provided an announcement. On March 24, 2026, Assembly Biosciences’ board compensation committee...

4M ago

ASMB

Assembly Biosciences Advances HSV-2 Drug ABI-1179 With Completion of Early-Stage Trial

Assembly Biosciences Inc ($ASMB) announced an update on their ongoing clinical study. Assembly Biosciences Inc. (ASMB) is running...

4M ago

ASMB

Assembly Biosciences files $400M mixed securities shelf

17:05 EDT Assembly Biosciences (ASMB) files $400M mixed securities shelf Published first on TheFly – the ultimate source...

4M ago

ASMB

Is ASMB a Buy, Before Earnings?

Assembly Biosciences Inc (ASMB) is scheduled to report 4th quarter earnings on 03/05/2026. Regarding Q4 estimates, Wall Street...

5M ago

ASMB

Gilead Partnership and Positive HSV Data De‑Risk Assembly Biosciences, Supporting Buy Rating and $50 Price Target

Assembly Biosciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from...

7M ago

ASMB

V7B FAQ

What was Assembly Biosciences’s price range in the past 12 months?

Assembly Biosciences lowest stock price was €15.05 and its highest was €33.50 in the past 12 months.

What is Assembly Biosciences’s market cap?

Assembly Biosciences’s market cap is €459.43M.

When is Assembly Biosciences’s upcoming earnings report date?

Assembly Biosciences’s upcoming earnings report date is Aug 12, 2026 which is in 20 days.

How were Assembly Biosciences’s earnings last quarter?

Assembly Biosciences released its earnings results on May 07, 2026. The company reported -€0.473 earnings per share for the quarter, beating the consensus estimate of -€0.569 by €0.096.

Is Assembly Biosciences overvalued?

According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Assembly Biosciences pay dividends?

Assembly Biosciences does not currently pay dividends.

What is Assembly Biosciences’s EPS estimate?

Assembly Biosciences’s EPS estimate is -0.63.

How many shares outstanding does Assembly Biosciences have?

Assembly Biosciences has 19,817,250 shares outstanding.

What happened to Assembly Biosciences’s price movement after its last earnings report?

Assembly Biosciences reported an EPS of -€0.473 in its last earnings report, beating expectations of -€0.569. Following the earnings report the stock price went down -1.321%.

Which hedge fund is a major shareholder of Assembly Biosciences?

Currently, no hedge funds are holding shares in DE:V7B

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Assembly Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

137.85%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Assembly Biosciences

Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.

Assembly Biosciences (V7B) Earnings & Revenues

Historic Earnings Reports

V7B Stock 12 Month Forecast

Average Price Target

€40.21

▲(57.68% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"€14","29":"€29","44":"€44","21.5":"€21.5","36.5":"€36.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":43.705224,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€43.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.20880608,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€40.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.58649264,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€37.59</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,21.5,29,36.5,44],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.15,25.654248,27.158496,28.662744,30.166992,31.67124,33.175488,34.679736,36.183984,37.688232,39.19248,40.696728,42.200976,{"y":43.705224,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.15,25.385292775384613,26.62058555076923,27.855878326153846,29.09117110153846,30.32646387692308,31.561756652307693,32.79704942769231,34.03234220307692,35.267634978461544,36.50292775384615,37.73822052923077,38.97351330461539,{"y":40.20880608,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.15,25.183576356923076,26.217152713846154,27.250729070769232,28.28430542769231,29.317881784615388,30.351458141538462,31.38503449846154,32.418610855384614,33.45218721230769,34.48576356923077,35.51933992615385,36.552916283076925,{"y":37.58649264,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.15,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >